Skip to content

US · SNY · DRUG MANUFACTURERS - GENERAL

Sanofi (SNY) intrinsic value and stock valuation

$46.52as of 2026-11-21 · Mkt cap 102.72B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sanofi DCF and intrinsic value

InvestorsCraft values SNY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SNY’s statements →

Sanofi Graham Number

Graham Number: $46.00d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Paris, IF 75008 sanofi.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$46.7B+4.6% 5y CAGRd
20112025
Net income
$7.81B-8.7% 5y CAGRd
20112025
Free cash flow
$10.1B+13.7% 5y CAGRd
20112025
Total equity
$71.7B+2.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$46.7B$44.3B$41.6B$40.6B$39.2B
Operating income$9.6B$7.25B$6.96B$10.2B$8.13B
Net income$7.81B$5.56B$5.4B$8.37B$6.22B
EPSd$3.2M$2.22M$2.15M$3.34M$2.48M
Operating cash flow$12.1B$9.08B$10.3B$10.5B$10.5B
Capital expenditure-$-1.99B-$-3.2B-$-1.62B-$-2.2B-$-2.04B
Free cash flow$10.1B$5.89B$8.64B$8.33B$8.48B
Total assets$126.8B$132.8B$126.5B$126.7B$120.2B
Total debt$20.3B$17.9B$18.7B$21.2B$22.4B
Net debt$12.7B$10.5B$9.99B$8.48B$12.3B
Total equity$71.7B$77.9B$74.4B$75.2B$69B
Cash and short-term investments$8.47B$7.93B$8.71B$12.7B$10.1B
Income statement
20252024202320222021
Revenue$46.7B$44.3B$41.6B$40.6B$39.2B
Cost of revenue$13B$13.2B$12.6B$11.9B$12.3B
Gross profit$33.7B$31.1B$29B$28.7B$26.9B
Research and development expenses$7.84B$7.39B$6.51B$6.5B$5.69B
Selling, general and administrative expenses$10.2B$9.18B$8.93B$8.74B$9.56B
Other expenses$5.99B$7.25B$6.59B$3.28B$3.55B
Operating expenses$24.1B$23.8B$22B$18.5B$18.8B
Cost and expenses$37.1B$37B$34.7B$30.4B$31B
Interest income$331M$457.5M$530.5M$169M$3.13M
Interest expense$626M$622.6M$512.8M$384.8M$377.4M
Depreciation and amortization$5.68B$3.59B$4.43B$3.11B$3.35B
Ebitda$12.5B$11B$11.4B$13.5B$11.5B
Operating income$9.6B$7.25B$6.96B$10.2B$8.13B
Total other income/expenses, net-$-3.58B-$-494M-$-845M-$-170M-$-289M
Income before tax$6.02B$6.76B$6.12B$9.99B$7.84B
Income tax expense$1.04B$1.2B$1.02B$1.91B$1.56B
Net income$7.81B$5.56B$5.4B$8.37B$6.22B
Weighted average shares outstanding$2.44B$2.5B$2.5B$2.5B$2.51B
Weighted average diluted shares outstanding$2.44B$2.5B$2.51B$2.5B$2.51B
Balance sheet
20252024202320222021
Cash and short-term investments$8.47B$7.93B$8.71B$12.7B$10.1B
Net receivables$11B$10.6B$11B$10.7B$9.79B
Inventory$10.2B$9.43B$9.67B$8.96B$8.72B
Total current assets$31B$42.6B$30.7B$34B$30.6B
Property, plant and equipment, net$11.5B$11.6B$11.8B$11.7B$12B
Goodwill and intangible assets$67.6B$66B$73.7B$71.5B$69.5B
Long-term investments$6.61B$3.26B$3.26B$3.22B$2.91B
Total non-current assets$95.9B$90.2B$95.8B$92.7B$89.7B
Total assets$126.8B$132.8B$126.5B$126.7B$120.2B
Accounts payable$7.36B$7.55B$7.33B$6.81B$6.18B
Short-term debt$4.61B$4.47B$2.6B$4.45B$3.45B
Deferred revenue$0.00$0.00$0.00$264M$319M
Total current liabilities$28.3B$29.2B$24.2B$24B$21.3B
Long-term debt$15.7B$13.4B$16.1B$16.8B$19B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$26.8B$25.8B$27.9B$27.6B$29.9B
Capital lease obligations$1.74B$1.91B$2.03B$1.9B$1.84B
Total liabilities$55.1B$54.9B$52.1B$51.6B$51.2B
Common stock$2.44B$2.53B$2.53B$2.52B$2.53B
Retained earnings$0.00$0.00$67.5B$66.7B$63B
Accumulated other comprehensive income (loss)$64.4B$70.6B$4.88B$6.11B$3.55B
Total equity$71.7B$77.9B$74.4B$75.2B$69B
Total investments$7.42B$3.75B$3.26B$3.22B$2.91B
Total debt$20.3B$17.9B$18.7B$21.2B$22.4B
Net debt$12.7B$10.5B$9.99B$8.48B$12.3B
Cash flow statement
20252024202320222021
Net income$5.57B$5.5B$5.4B$8.37B$6.22B
Depreciation and amortization$6.46B$3.59B$3.78B$3.42B$3.35B
Stock-based compensation$0.00$0.00$0.00$245M$244M
Change in working capital$2.03B-$-615M$764M-$-707M$1.41B
Accounts receivable-$-1.36B-$-28M-$-397M-$-777M$185M
Inventory-$-44.02M-$-477M-$-840M-$-927M-$-357M
Accounts payable$449.2M$789M$402M$452M$451M
Net cash provided by operating activities$12.1B$9.08B$10.3B$10.5B$10.5B
Investments in property, plant and equipment-$-4.08B-$-3.24B-$-3.25B-$-2.2B-$-2.04B
Acquisitions, net$955.9M-$-2.52B$1.01B-$-858M-$-5.59B
Net cash used for investing activities-$-2.76B-$-4.41B-$-6.2B-$-2.08B-$-7.3B
Common stock issued$199.8M$187M$195M$188M$186M
Common stock repurchased-$-5.68B-$-302M-$-593M-$-497M-$-382M
Dividends paid-$-5.39B-$-4.7B-$-4.45B-$-4.17B-$-4.01B
Net cash used for financing activities-$-9.26B-$-5.76B-$-8.05B-$-5.82B-$-7.06B
Net change in cash$970.5M-$-1.27B-$-4.03B$2.64B-$-3.82B
Cash at end of period$8.68B$7.44B$8.71B$12.7B$10.1B
Operating cash flow$12.1B$9.08B$10.3B$10.5B$10.5B
Capital expenditure-$-1.99B-$-3.2B-$-1.62B-$-2.2B-$-2.04B
Free cash flow$10.1B$5.89B$8.64B$8.33B$8.48B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sanofi

        Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

        CEO
        Belén Garijo López
        Employees
        76.49K
        Beta
        0.28

        Explore

        Frequently asked questions

        What is the intrinsic value of Sanofi (SNY)?

        Sanofi (SNY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SNY undervalued?

        SNY trades at a price of $46.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.